Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. Academic Article uri icon

Overview

abstract

  • In this study, the protective efficacy of a novel recombinant bacille Calmette GĂ©urin (BCG) strain (rBCG-AEI) expressing fusion protein the antigen 85B (Ag85B)- the 6-kDa early secreted antigen target (ESAT-6)-IFN-gamma against Mycobacterium tuberculosis H37Rv in mice was evaluated. The immunogenicity study showed that rBCG-AEI could induce higher specific antibody titers and significantly increase cellular immune response than BCG, or rBCG-A strain (expressing Ag85B), or rBCG-AE strain (expressing fusion protein Ag85B-ESAT-6). The protective experiment demonstrated that rBCG-AEI could confer similar or even better protective efficacy against M. tuberculosis infection compared with others in organ bacterial loads, lung histopathology and net weight gain or loss. The results suggested that rBCG-AEI is a potential candidate for further study.

publication date

  • October 4, 2007

Research

keywords

  • Acyltransferases
  • Antigens, Bacterial
  • Bacterial Proteins
  • Bacterial Vaccines
  • Interferon-gamma
  • Mycobacterium bovis
  • Tuberculosis
  • Tuberculosis Vaccines

Identity

Scopus Document Identifier

  • 35948944602

Digital Object Identifier (DOI)

  • 10.1111/j.1574-695X.2007.00322.x

PubMed ID

  • 17919299

Additional Document Info

volume

  • 51

issue

  • 3